Clinical trial · Interventional
New Treatment of Common Wart
Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts
NCT07543926CI-TRIAL-00109011not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Common Warts (Verruca Vulgaris) | Verruca Vulgaris | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PRF group | Biological | — | UNRESOLVED |
| Vitamin D | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- group 1 PRF injection
- interventionNames
- Biological: PRF group
- type
- ACTIVE_COMPARATOR
- label
- group 2 vitamin D injection
- interventionNames
- Drug: Vitamin D
Primary outcomes (2)
- measure
- treatment of common wart by PRF injection ( Mild response: < 50% reduction in lesion size , Moderate response: ≥ 50% reduction in lesion size , to measure the change in lesion size , is the patient satisfied or not )
- timeFrame
- 1 session every 2 weeks for 3 months
- description
- treatment of common wart by intralesional injection of PRF
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \- Age more than or equal to 18 years * Clinically and dermoscopically confirmed Common warts of both sex * patient not receiving previous treatment at least one month before recruitment in our study * Single or multiple lesions suitable for injection. Exclusion Criteria: * Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g/dl , thrombocytopenia : platelet count below 150,000 /µL ) Infectious Diseases , Local bacterial or fungal infection at the lesions . Pregnancy, Lactation , patients who has hypersensitivity of vitamin D .
References
Publications (0)
Data not yet available
No reference posted for this study.